Clinical Trials Logo

Clinical Trial Summary

Clinicians tend to overuse antibiotics in snake bite despite evidence from three previous clinical trials that failed to show a benefit. But, none of these trials was done in India. Further, the species of snake in two of these trials was quite different from that seen in the Indian setting limiting generalization of these findings. Hence, home-grown evidence is needed to persuade clinicians to use antibiotics rationally.


Clinical Trial Description

Snake bite is a common clinical problem in India and elsewhere, affecting agricultural workers and rural population, resulting in thousands of deaths every year. Apart from causing systemic manifestations such as coagulopathy, acute renal failure, and neuroparalysis, local effects of the venom manifest as swelling of the bitten limb. Despite administration of adequate antivenom, the limb swelling progresses in the first 48-72 hours accompanied by considerable pain. Often the limb swelling is accompanied by formation of blebs and gangrenous skin changes. At times, the limb swelling is severe enough to result in compartment syndrome, necessitating surgical interventions such as fasciotomy and debridement. Animal bites are typically associated with a risk of infection by the oral flora. Likewise, apart from releasing the venom, inoculation of oral flora as a result of snake bite could result in local infectious complications adding to the deleterious effects of the snake venom. Observational studies suggest that the risk of infection following simple bites on the lower limbs is much less than what is often believed, and evidence from clinical trials also does not support routine use of antibiotics in snake bite. For this reason, clinical practice guidelines do not recommend routine prophylactic use of antibiotics in snake bite. But, in reality, many clinicians continue to use antibiotics routinely in all venomous snake bites hoping to prevent a local infection. While such a strategy may not reduce the risk of infection, it would result in overuse of antibiotics promoting antimicrobial resistance and escalating treatment costs. The investigators hypothesize that clinically-directed use of antibiotics would be non-inferior to routine use in preventing local infectious complications of snake bite, while being superior in reducing the antibiotic consumption. Non-inferiority would be inferred if the one-sided 95% CI of the difference does not exceed 10% in favour of the routine use arm. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02570347
Study type Interventional
Source Jawaharlal Institute of Postgraduate Medical Education & Research
Contact
Status Terminated
Phase Phase 4
Start date May 3, 2016
Completion date March 31, 2020

See also
  Status Clinical Trial Phase
Completed NCT03326492 - Evaluation of Anti-venoms Serum in Africa
Completed NCT03890016 - Study Comparing Modified Lee White Clotting Time Against Twenty Minute Whole Blood Clotting Test in Snakebite Victims
Withdrawn NCT02694952 - Non-inferiority Trial of Two Snake Antivenoms in CAR (PAVES) N/A
Completed NCT00270777 - Improving Safety of Antivenom in People Bitten by Snakes Phase 4
Completed NCT04520282 - Hemostatic Variables In Snakebite Study
Completed NCT01864200 - Randomized, Double-Blind, Placebo-Controlled Study: CroFab® vs Placebo for Copperhead Snake Envenomation Phase 4
Completed NCT04470791 - Cryotherapy as a Coadjuvant in Crotaline Snakebite Management With Antivenom. N/A